Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P14060
UPID:
3BHS1_HUMAN
Alternative names:
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I; 3-beta-hydroxy-5-ene steroid dehydrogenase; 3-beta-hydroxy-Delta(5)-steroid dehydrogenase; 3-beta-hydroxysteroid 3-dehydrogenase; Delta-5-3-ketosteroid isomerase; Dihydrotestosterone oxidoreductase; Steroid Delta-isomerase; Trophoblast antigen FDO161G
Alternative UPACC:
P14060; A8K691; Q14545; Q8IV65
Background:
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 plays a pivotal role in steroid hormone biosynthesis. It catalyzes essential conversions, such as pregnenolone to progesterone and DHEA to 4-androstenedione, impacting various physiological processes. Known by multiple names, including Dihydrotestosterone oxidoreductase, it controls the bioavailability of active androgens and estrogens, crucial for reproductive and metabolic health.
Therapeutic significance:
Understanding the role of 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 could open doors to potential therapeutic strategies. Its involvement in the synthesis of key steroid hormones suggests its potential as a target in treating hormonal imbalances and disorders related to steroid biosynthesis.